Armata Pharmaceuticals (ARMP) Fundamental Analysis: Revenue, Earnings & Valuation

4.14 / 10

Netural

Fundamental health scores 4.1/10, indicating a balanced but modest base. Revenue‑MV and Profit‑MV are positive, supporting earnings strength. However, Fixed‑assets turnover and Income‑tax‑to‑profit ratios are weak, dragging the overall assessment. Caution is advised despite decent revenue metrics.

Analysis Checks(7/10)

Revenue-MV

Value-2.93

Score2/3

Weight16.74%

1M Return8.05%

Inventory turnover ratio

Value47.57

Score3/3

Weight14.48%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.07%

1M Return1.67%

Profit-MV

Value0.41

Score2/3

Weight13.62%

1M Return6.36%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.33%

1M Return0.21%

Current assets turnover ratio

Value0.27

Score1/3

Weight-0.30%

1M Return-0.17%

Fixed assets turnover ratio

Value0.07

Score1/3

Weight-1.77%

1M Return-1.13%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight7.20%

1M Return4.08%

Asset-MV

Value-0.48

Score2/3

Weight33.28%

1M Return13.10%

Cash-MV

Value-0.09

Score2/3

Weight13.35%

1M Return6.19%

Is ARMP undervalued or overvalued?

ARMP scores 4.14/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -3544.03% net margin, -1.80 P/E ratio, -1.43 P/B ratio, and -823.08% earnings growth, these metrics solidify its Netural investment rating.